ImClone Motion Denied In Erbitux Case
A federal judge on Friday dismissed ImClone Systems Inc.'s motion for summary judgment, thus setting the stage for a trial in an ongoing patent infringement battle over the cancer drug Erbitux....To view the full article, register now.
Already a subscriber? Click here to view full article